Original article
99
Serum chemerin level in chronic kidney disease
Samiha Abo Eiyazeed Abd Raboa, Nagwa Abdel Ghaffar Mohamedb,
Naglaa Abd Elfattah Tawfika, Marwa Mosa HamedF
a
Department of Internal Medicine, Faculty of
Medicine for Girls, Al Azhar University, Cairo,
Egypt, bDepartment of Clinical and Chemical
Pathology, National Research Center, Cairo,
Egypt, cDepartment of Internal Medicine,
General Helwan Hospital, Cairo, Egypt
Correspondence to Naglaa Abd Elfattah
Tawfik, PhD, Faculty of Medicine, Assiut
University, Assiut, Egypt; Tel: 01148722557;
e-mail: naglaaelmokdem@yahoo.com
Received 14 July 2016
Accepted 30 August 2016
The Egyptian Journal of Internal Medicine
2016, 28:99–107
Background
Chronic kidney disease (CKD) is a progressive loss in renal function over a period of
months or years. In the metabolic association of an elevated circulating chemerin
level in the context of uremia demonstrate that high chemerin levels predict a better
survival in CKD patients. The aim of the study was to measure serum chemerin and
to correlate it with other parameters in CKD patients.
Patients and methods
This study was conducted on 40 patients with CKD, including 20 patients with endstage renal disease under regular hemodialysis and 20 patients with renal
impairment on conservative therapy who have not started hemodialysis, and 22
apparently healthy participants serving as the control group. Human chemerin is
determined by sandwich enzyme immunoassay.
Results
There is a highly statistically significant difference in mean serum chemerin and
mean serum high-sensitivity C-reactive protein (hs-CRP) in the patient groups in
comparison with the control group. In addition, there was a highly statistically
significant difference between control group, under hemodialysis group, and renal
impairment group as regards serum chemerin and serum hs-CRP. A positive
correlation between serum chemerin and hs-CRP studied in the under
hemodialysis group, renal impairment group, and in all patients’ group.
Conclusion
A significantly higher chemerin level in patients with impaired kidney function
compared with the normal control group, and a high increase in patients under
hemodialysis compared with the other two groups.
Keywords:
chemerin, chronic kidney disease, high-sensitivity C-reactive protein, insulin
Egypt J Intern Med 28:99–107
© 2017 The Egyptian Journal of Internal Medicine
1110-7782
Introduction
Chronic kidney disease (CKD), also known as
chronic renal disease, is a progressive loss in renal
function over a period of months or years [1]. CKD is
defined as kidney damage or glomerular filtration
rate (GFR) less than 60 ml/min/l.73 m2 for 3 months
or more, regardless of cause [2]. Kidney failure is
defined as either (a) GFR less than 15 ml/min/
1.73 m2, which is accompanied in most cases by
signs and symptoms of uremia, or (b) a need to
start kidney replacement therapy (dialysis or
transplantation) [3].
The most common causes of CKD are diabetes mellitus,
hypertension, and glomerulonephritis. Together, these
comprise ∼75% of all adult cases [4]. The major
outcomes of CKD, regardless of cause, include progression to kidney failure, complications of decreased
kidney function, and cardiovascular disease. Increasing
evidence indicates that some of these adverse outcomes
can be prevented or delayed by early detection and
treatment [5].
Chemerin, also known as tazarotene-induced gene 2
(TIG2) and retinoic acid receptor responder 2
(RARRES2), is a newly discovered adipokine highly
expressed by a number of tissues and organs including
adipose tissue, liver, pancreas, lung, and skeletal
muscles [6].
Several specific functions have been related to
chemerin so far, including regulation of specific
immune cell migration [7,8], regulation of adipogenesis
[9], and anti-inflammatory effects on macrophages [10].
Chemerin is secreted as an 18-kDa inactive proprotein
formed of 143 amino acids, termed as prochemerin [11].
Enzymes that contribute to activation of chemerin and
promote the conversion of inactive prochemerin into
the active form chemerin include serine proteases of the
This is an open access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-ShareAlike 3.0 License, which
allows others to remix, tweak, and build upon the work
noncommercially, as long as the author is credited and the new
creations are licensed under the identical terms.
© 2017 The Egyptian Journal of Internal Medicine | Published by Wolters Kluwer - Medknow
DOI: 10.4103/1110-7782.200964
100
The Egyptian Journal of Internal Medicine, Vol. 28 No. 3, July-September 2016
Group II included 40 CKD patients (19 male and
21 female); their ages ranged between 18 and 62
years, with a mean age of 43±12.17 years. This
group was further divided into two groups:
Group IIa included 20 patients with end-stage renal
disease under regular hemodialysis (10 male and 10
female); their ages ranged between 18 and 60 years,
with a mean age of 41.35±11.95 years.
Group IIb included 20 patients with renal impairment on conservative therapy who have not started
hemodialysis yet (nine male and 11 female); their ages
ranged between 19 and 62 years, with a mean age of
41.75±12.70 years.
coagulation, fibrinolytic, and inflammatory cascades,
circulating carboxypeptidases, as well as staphopain B,
a cysteine protease secreted by Staphylococcus aureus,
which is found in some pathological conditions [11].
Prochemerin, the inactive form of chemerin, can be
converted to chemerin by either serine proteases or
cysteine proteases. Serine proteases result in the
production of stimulatory chemerin, whereas cysteine
proteases result in the production of inhibitory
chemerin, termed as inhibitory peptide chemerin 15
[12].
Chemerin has different roles at the physiological level.
The main role of chemerin has been proven to be
related to the adipose tissue. Chemerin can enhance
insulin sensitivity of adipocytes by stimulating the
process of glucose transport through different tissues
[13].
The metabolic associations of an elevated circulating
chemerin level in the context of uremia demonstrate
that high chemerin levels predict a better survival in
CKD patients. Furthermore, associations between
circulating chemerin levels and GFR, insulin resistance,
blood lipids and inflammatory markers, but not with body
fat, have been reported [14]. A study has reported
circulating chemerin in a CKD population, finding
increased levels in hemodialysis patients, as well as an
inverse correlation with residual renal function [15].
However, as links between circulating chemerin and
inflammation, body composition, and metabolism were
not investigated, they explored these associations, as well
as the possibility that chemerin predicted 5-year mortality
in an observational cohort study of incident dialysis
patients.
The aim of the study was to find the role of serum
chemerin in CKD patients.
Patients and methods
This study was conducted on 40 patients with CKD
and 22 apparently healthy participants serving as the
control group. All patients were selected from Internal
Medicine Department, Al Zahraa University Hospital,
and Nephrology Department Medical Insurance
Hospital, Helwan in the period between December
2013 and March 2014.
Group I included 22 healthy participants as the
control group (11 male and 11 female); their ages
ranged between 22 and 65 years, with a mean age of
43±13.11 years.
Exclusion criteria
Patients with acute or chronic known infection,
cardiovascular disease, hypertension, diabetes mellitus,
chronic liver disease (hepatitis B or C), or HIV infection
were excluded.
After taking a written consent from all participants
participating in this study and approval of ethical
committee of Faculty of Medicine, Al-Azhar
University, they were subjected to the following tests:
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Full history and full clinical examination.
Complete blood picture (CBC).
Fasting blood glucose.
Kidney function tests (serum urea and serum
creatinine).
Serum glutamic oxaloacetic transaminase (SGOT)
and AGPT.
Lipid profile [total cholesterol, triglyceride (TG),
high-density lipoprotein (HDL) and low-density
lipoprotein (LDL)].
Serum insulin.
Serum high-sensitivity C-reactive protein (hs-CRP).
Serum chemerin.
Five milliliters of fasting (12–16 h) venous blood samples
were taken from each subject in the study and divided
into two parts: the first part was 2 ml of blood and
was put in a tube containing EDTA for CBC
determination on Coulter Counter T890 (Coulter
Counter, Harpenden, UK). The second part was 3 ml
of blood and was left to clot and the serum was separated
by centrifugation for 15 min at 3000g. Samples should
be assayed immediately after collection or they should
be stored at −20°C for determination of fasting blood
glucose (which is determined immediately on Hitachi
912 autoanalyzer using colorimetric techniques) and
kidney function tests. SGOT, serum glutamic pyruvic
transaminase (SGPT), lipid profile, insulin, and chemerin were also determined.
Serum chemerin level in CKD Abd Rabo et al.
(1) The determination of serum urea, creatinine,
SGOT, SGPT, total cholesterol, and TG was
performed on Hitachi 912 auto analyzer (Roche
Diagnostics GmbH, D-68298 Mannheim, USA)
by colorimetric techniques. For determination of
HDL-cholesterol, phosphotungestic acid and
magnesium ions are used for precipitating all
lipoproteins, except HDL fraction, which was
present in the supernatant and measured by the
autoanalyzer. LDL-cholesterol was measured by
Friedwald formula [16].
(2) Fasting serum insulin was determined using
radioimmunoassay [17]. Insulin resistance was
calculated as HOMA-IR using the following
equation [18]:
HOMA IR ¼
Fasting glucose ðmg=dlÞ × fasting insulin ðμIU=mlÞ
:
405
(3) Determination of hs-CRP was done by a
solid-phase immunosorbent assay (enzyme-linked
immunosorbent assay) [19], and the kit was supplied
by DRG International Inc. (Springfield, New Jersey,
USA).
(4) Human chemerin is determined by sandwich enzyme
immunoassay [20], and the kit was supplied from bio
Vendor (Bio Vendor GmbH, Heidelberg, Germany).
101
by post-hoc least significant difference test when the
comparison showed significant difference. Spearman’s
correlation coefficients were used to assess the relation
between two quantitative parameters in the same group.
Receiver operating characteristic curve was used to assess
the best cutoff point with its sensitivity, specificity, positive
predictive value, and negative predictive value.
Results
Table 1 shows a comparison between control group I
and patient group II regarding age, sex, and BMI, and
there was no statistically significant difference between
patient and control groups regarding age and sex. In
addition, there was a high statistically significant
difference in BMI between the patient and control
groups.
Table 2 shows a comparison between control group I
and whole patient group II, with a highly statistically
significant difference in mean serum urea, mean serum
creatinine, mean serum HDL, mean serum LDL, mean
serum TG, mean serum SGOT, mean serum insulin,
and HOMA index and CBC in the patient group in
comparison with the control group. It also shows a
statistically significant difference in cholesterol in the
patient group in comparison with the control group.
Table 3 shows a highly statistically significant difference
in mean serum chemerin and mean serum hs-CRP in
the patient group in comparison with the control group.
Statistical analysis
Data were collected, coded, revised, and entered to
the Statistical Package for Social Science version 20
(IBM SPSS version 20, USA). The qualitative data
were presented as number and percentages and as
mean, SD, and ranges with the quantitative data.
Comparison between groups with qualitative data was
done by using χ 2-test, whereas the comparison between
two groups with quantitative data was done by
independent t-test; more than two groups were
compared using one-way analysis of variance followed
Table 4 reveals a nonsignificant difference between the
three groups regarding age and sex. In addition, there
was a highly significant increase in BMI in both patient
groups compared with the control group.
Table 5 shows a highly statistically significant difference
between control group I, under hemodialysis group IIa,
and renal impairment group IIb in CBC, mean serum
urea, mean serum creatinine, mean serum SGPT,
Table 1 Comparison between control group I and patient group II regarding age, sex, and BMI
Control group [n (%)]
χ 2-Test
Patient group [n (%)]
χ
2
P-value
Sex
Female
Male
11 (50.0)
11 (50.0)
21 (52.5)
19 (47.5)
0.036
0.851
43.23±13.11
41.55±12.17
0.505
0.615
22–65
18–62
0.154
0.000
Age
Mean±SD
Range
BMI
Mean±SD
19.5±4.33
26.14±3.6
18–26
19.04–41.4
Range
P>0.05, NS. P<0.05, S. P<0.01, HS.
102
The Egyptian Journal of Internal Medicine, Vol. 28 No. 3, July-September 2016
Table 2 Comparison between patients and control group regarding different laboratory parameters
Independent t-test
Control group
Patient group
Mean±SD
Mean±SD
t
P-value
WBCs
5.76±0.81
6.87±1.92
−2.599
0.012
RBCs
Hb
4.11±0.34
12.10±0.73
3.61±1.00
9.90±1.91
2.272
5.169
0.027
0.000
Urea
18.50±4.07
121.63±48.16
−9.988
0.000
Creatinine
0.87±0.20
5.51±3.65
−5.940
0.000
SGPT
15.09±4.32
16.16±8.08
−0.574
0.568
SGOT
21.41±3.14
16.70±9.07
2.352
0.022
Cholesterol
154.18±21.88
181.03±52.34
−2.291
0.025
TG
90.68±16.62
115.58±39.15
−2.837
0.006
HDL
LDL
105.86±11.87
51.77±6.81
43.85±14.05
126.83±18.78
17.533
−18.050
0.000
0.000
FBG
94.73±11.31
94.93±13.93
−0.056
0.956
FSI
9.30±1.76
15.87±3.07
−9.218
0.000
HOMA index
2.20±0.49
3.72±0.87
7.677
0.000
HDL, high-density lipoprotein; LDL, low-density lipoprotein; RBC, red blood cell; TG, triglyceride; WBC, white blood cell.
Table 3 Comparison between control group I and patient group II regarding serum chemerin and serum high-sensitivity Creactive protein
Chemerin
Control group
Patient group
Mean±SD
Mean±SD
121.35±18.82
4.65±1.82
hs-CRP
Independent t-test
t
P-value
290.29±98.18
−7.962
0.000
15.23±7.11
−6.839
0.000
hs-CRP, high-sensitivity C-reactive protein.
Table 4 Comparison between the three studied groups control I, under hemodialysis IIa, and renal impairment IIb groups
regarding age, sex, and BMI
Control group I [n (%)]
Under hemodialysis IIa [n (%)]
χ 2-Test
Renal impairment IIb [n (%)]
χ2
P-value
0.136
0.934
0.131
0.878
20.368
0.000
Sex
Female
11 (50.00)
10 (50.00)
11 (55.00)
Male
11 (50.00)
10 (50.00)
9 (45.00)
Age
Mean±SD
43.23±13.11
41.35±11.95
41.75±12.70
Range
22–65
18–60
19–62
19.50±4.33
26.12±4.87
26.18±1.84
18–26
19.04–41.4
23.2–30
BMI
Mean±SD
Range
and mean serum SGOT. There was a highly statistically
significant difference between control group I, under
hemodialysis IIa, and renal impairment IIb in mean
serum concentrations of cholesterol, TG, HDL,
LDL, fasting serum insulin (FSI), and mean HOMA.
However, there was no statistically significant difference
between control group, under hemodialysis group, and
renal impairment group in mean fasting blood glucose
(FBG).
Table 6 reveals that comparisons between the control
group I and both patient groups and between the two
patient groups showed highly statistically significant
difference in CBC, mean serum urea, and mean serum
creatinine (P<0.01), and a statistically significance in
mean serum SGPT when comparing the control
group with group IIa (P<0.05). The comparison
between the control group I and renal impairment
IIb group showed a highly statistically significant
difference in mean serum urea and mean serum
creatinine (P<0.01). Post-hoc analysis for laboratory
parameters among the three studied groups: The
comparison between the control group versus the
under hemodialysis group showed a high statistical
significance in TG, HDL, LDL, FSI, and HOMA
index (P<0.01). The comparison between the control
group versus renal impairment group showed high
statistical significance in cholesterol, HDL, LDL,
FSI, and HOMA index (P<0.01). The comparison
between the patients under hemodialysis versus renal
Serum chemerin level in CKD Abd Rabo et al.
103
Table 5 Comparison between the three studied groups, control I, under hemodialysis IIa, and renal impairment IIb groups,
regarding laboratory data
Control group I
Under hemodialysis IIa
Renal Impairment IIb
One-way ANOVA
Mean±SD
Mean±SD
Mean±SD
F
P-value
WBCs
5.76±0.81
7.75±2.20
6.00±1.05
11.260
0.000
RBCs
4.11±0.34
3.18±1.20
4.04±0.45
9.554
0.000
Hb
12.10±0.73
8.60±1.76
11.20±0.92
46.930
0.000
Urea
18.50±4.07
142.60±48.16
100.65±38.92
67.930
0.000
Creatinine
0.87±0.20
7.19±3.35
3.84±3.18
30.295
0.000
SGPT
15.09±4.32
12.52±4.62
19.80±9.20
6.705
0.002
SGOT
21.41±3.14
12.65±5.74
20.75±10.07
10.378
0.000
Cholesterol
TG
154.18±21.88
90.68±16.62
151.70±54.58
134.20±35.76
210.35±28.87
96.95±33.73
15.957
12.935
0.000
0.000
HDL
105.86±11.87
49.60±16.02
38.10±8.86
176.745
0.000
LDL
51.77±6.81
121.57±16.57
132.08±19.78
175.546
0.000
FBG
94.73±11.31
95.48±9.50
94.37±17.53
0.037
0.964
FSI
9.30±1.76
16.37±3.55
15.37±2.49
43.452
0.000
HOMA index
2.18±0.48
3.85±0.89
3.57±0.84
30.281
0.000
ANOVA, analysis of variance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RBC, red blood cell; TG, triglyceride; WBC,
white blood cell.
Table 6 Post-hoc analysis for the laboratory data between the three studied groups
Parameters
Post-hoc analysis: LSD test
Control vs. under hemodialysis
Control vs. renal impairment
Under hemodialysis vs. renal impairment
WBCs
0.000
0.595
0.000
RBCs
0.000
0.767
0.001
Hb
0.000
0.020
0.000
Urea
0.000
0.000
0.000
Creatinine
0.000
0.001
0.000
SGPT
SGOT
0.046
0.000
0.243
0.756
0.403
0.000
Cholesterol
0.831
0.000
0.000
TG
0.000
0.496
0.000
HDL
0.000
0.000
0.000
LDL
0.000
0.000
0.033
FSI
0.000
0.000
0.244
HOMA index
0.000
0.000
0.256
HDL, high-density lipoprotein; LDL, low-density lipoprotein; LSD, least significant disease; RBC, red blood cell; TG, triglyceride; WBC,
white blood cell.
Table 7 Comparison between the three studied groups regarding serum chemerin and serum high-sensitivity C-reactive protein
Chemerin
hs-CRP
Control group
Under hemodialysis
Renal impairment
Mean±SD
Mean±SD
Mean±SD
One-way ANOVA
121.35±18.82
373.55±55.14
207.03±46.40
189.703
0.000
4.65±1.82
20.76±5.79
9.70±2.38
101.764
0.000
F
P-value
ANOVA, analysis of variance; hs-CRP, high-sensitivity C-reactive protein.
impairment patients showed high statistical
significance in cholesterol, TG, and HDL (P<0.01).
It also showed a statistical significance in LDL
(P<0.05).
Table 8 shows a post-hoc analysis for serum chemerin
and serum hs-CRP among three studied groups, which
show a highly statistical significance on both studied
parameters (P<0.01).
Table 7 shows a comparison between the three
studied groups regarding mean serum chemerin and
mean serum hs-CRP. There was a high statistically
significant difference between the control group, under
hemodialysis group, and renal impairment group in serum
chemerin and serum hs-CRP.
Table 9 demonstrates the correlation between serum
chemerin and studied parameters in the under
hemodialysis group, renal impairment group, and
in all patients’ group; there was a significant
positive correlation between chemerin and urea,
creatinine, FSI, HOMA index, and hs-CRP
104
The Egyptian Journal of Internal Medicine, Vol. 28 No. 3, July-September 2016
Table 8 Post-hoc analysis for serum chemerin and serum high-sensitivity C-reactive protein among the three studied groups
Parameters
Post-hoc analysis: LSD test
Control vs. under hemodialysis
Control vs. renal impairment
Under hemodialysis vs. renal impairment
Chemerin
0.000
0.000
0.000
hs-CRP
0.000
0.000
0.000
hs-CRP, high-sensitivity C-reactive protein; LSD, least significant difference.
Table 9 Correlation between chemerin and the studied parameters in under hemodialysis group, renal impairment group, and in
all patients group
Parameters
Chemerin
Under hemodialysis
r
P-value
Renal impairment
r
All patients
P-value
r
P-value
Age
0.079
0.741
−0.074
0.755
−0.027
0.868
BMI
−0.002
0.992
−0.211
0.373
−0.123
0.451
WBCs
0.313
0.179
−0.147
0.536
0.405**
0.010
RBCs
0.107
0.652
−0.265
0.259
−0.516**
0.001
Hb
−0.026
0.912
−0.334
0.150
−0.653**
0.000
Urea
Creatinine
0.836**
0.999**
0.000
0.000
0.358
0.995**
0.121
0.000
0.677**
0.918**
0.000
0.000
SGPT
0.403
0.078
−0.149
0.531
−0.366*
0.020
SGOT
0.167
0.481
0.171
0.471
−0.330*
0.038
Cholesterol
0.017
0.944
−0.208
0.380
−0.619**
0.000
TG
0.422
0.064
−0.143
0.547
0.530**
0.000
HDL
0.176
0.457
−0.204
0.388
0.376*
0.017
LDL
−0.167
0.481
−0.259
0.271
−0.313*
0.049
FBG
FSI
−0.124
0.995**
0.602
0.000
−0.108
0.967**
0.651
0.000
−0.013
0.591**
0.937
0.000
HOMA index
0.848**
0.000
0.526*
0.017
0.440**
0.004
hs-CRP
0.992**
0.000
0.983**
0.000
0.994**
0.000
HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; LSD, least significant disease;
RBC, red blood cell; TG, triglyceride; WBC, white blood cell. *Significance. **Highly significance.
among the hemodialysis patients (P<0.01). In
addition, there was a positive correlation between
serum chemerin and creatinine, FSI, HOMA
index, and hs-CRP in renal impairment patients
(P<0.01). There was also a correlation between
chemerin and white blood cells, red blood cells
(RBCs), Hb, urea, creatinine, cholesterol, TG,
LDL, HDL, FBG, FSI, SGOT, SGPT, and hsCRP in all patients’ group (P<0.01).
Table 10 Receiver operating characteristic curve between
patients and controls regarding serum chemerin
Cut off point
AUC
Sensitivity
Specificity
PPV
NPV
>147.5
100.0
100.00
100.00
100.0
100.0
AUC, area under the curve; NPV, negative predictive value; PPV,
positive predictive value.
Figure 1
Table 10 and Fig. 1 shows that serum chemerin level is
considered to have better positive predictive value,
sensitivity, and specificity.
Table 11 and Fig. 2 show that chemerin level is
considered to have a better positive predictive value,
sensitivity, and slightly better specificity.
Discussion
We aimed in the present work to study serum chemerin
levels and to determine their relation to patients with
CKD.
Receiver operating characteristic (ROC) curve analysis between
patients under hemodialysis and patients with renal impairment
regarding serum chemerin.
Serum chemerin level in CKD Abd Rabo et al.
Table 11 Receiver operating characteristic curve between
patients under hemodialysis and patients with renal
impairment regarding serum chemerin
Cut off point
AUC
Sensitivity
Specificity
PPV
NPV
274.9
99.2
100.0
90.0
90.9
100.0
AUC, area under the curve; NPV, negative predictive value; PPV,
positive predictive value.
Figure 2
Receiver operating characteristic (ROC) curve between patients
under hemodialysis and patients with renal impairment regarding
serum chemerin.
In this study, we compared three studied groups as
regards age, sex, and BMI, and we found no significant
difference in both age and sex, but we found a
significant increase in BMI in patients more than
the control group, which may be because of the
increase in water loading and obesity in the diseased
group, which was in contrast to the study by Dorte et al.
[21], who showed that CKD patients had a significantly
lower BMI compared with control patients, which
results from the environmental and ethnic difference.
In our study, we found a statistical significance as
regards Hb concentration, white blood cells, RBCs,
FBG, FSI, and HOMA index between the control
group and the patient groups. This was found also by
Kilpatrick et al. [22] and Dorte et al. [21].
The studies found that patients in the renal impairment
group and under hemodialysis group had anemia due to
decreased erythropoietin (the most important factor),
iron deficiency, folate deficiency, hemolysis, and bone
marrow fibrosis because of the shortened life span of
RBCs.
As regards lipid profile (cholesterol, TGs, HDL, LDL),
there were significant differences between the control
group and patient group, which was in agreement with
Kilpatrick et al. [22] and Dorte et al. [21]. Dysregulation
of lipid metabolism in the patient group can contribute to
105
atherogenic diathesis and possibly to progression
of renal disease and impaired energy metabolism in
CRF. Hyperlipidemia can potentially accelerate
progression of renal disease by several mechanisms.
First, reabsorption of fatty acids, phospholipids, and
cholesterol contained in the filtered proteins (albumin
and lipoproteins) by tubular epithelial cells can stimulate
tubulointerstitial inflammation, foam cell formation, and
tissue injury. Second, accumulation of lipoproteins in
glomerular mesangium can promote matrix production
and glomerulosclerosis [23].
In this study, we found that chemerin level was
significantly higher among patients in the under
hemodialysis group compared with the other two
groups. This was supported by Dörte et al. [21] and
Fouque et al. [24], who reported that chemerin was
more than two-fold higher in CKD patients compared
with the control group. Studies found that elevated
serum chemerin levels may be a consequence of
impaired kidney in patients. Impaired clearance or
catabolism of chemerin in kidney may lead to the
accumulation of chemerin in the blood. This suggests
that elevated serum chemerin levels are significantly
associated with serum creatinine and urea in renal
impairment and under hemodialysis patients. In our
study, we found that chemerin level was significantly
higher among the under hemodialysis patient group
compared with renal impairment patient group
because the serum urea and creatinine were higher in
the under hemodialysis patient group compared with the
renal impairment patient group, as the sample from the
under hemodialysis patient group was collected before
dialysis.
In our study, there is a significant positive correlation
between chemerin level versus serum creatinine and urea.
Dörte et al. [21] and Pfau et al. [15] support the same
result which that referred to infiltration of kidney
glomeruli by inflammatory cell like monocyte and
macrophage result in glomerular injury and tubuleinterstitial damage that decrease the functional capability of kidney to excrete waste products. Another
explanation was obtained by the Pfau et al. [15,] who
postulated that impaired kidney function by overproduction and impaired degradation of extracellular
matrix components leads to their accumulation in
basement membrane and mesangial region in glomerulus or may be because of the presence of hyperglycemia, glomerular hypertension, advanced glycation
end products, and activation of polyol pathway [15].
In our study, there is a significant positive correlation
between chemerin level and cholesterol, TG, HDL,
106
The Egyptian Journal of Internal Medicine, Vol. 28 No. 3, July-September 2016
and LDL This was supported by Xu et al. [25], who
reported that chemerin is a proinflammatory cytokine
activating immune cells, and it might play a role in the
inflammation of adipose tissue that occurs in obesity.
In addition, in our study, there is a positive significant
correlation between chemerin level concentrations and
FBG, FSI, and HOMA-IR index in the CKD group
patients. This result agrees with Sell and Eckel [6];
Dorte et al. [21]; Lehrke et al. [26]; and Weigert et al.
[27]. Sell and Eckel attributed this to the fact that
chemerin induces insulin resistance in peripheral tissue
such as skeletal muscle and inhibits glucose uptake.
Another explanation was obtained by Weigert et al.
[27], who postulated that, in adipocytes, chemerin
has the opposite effect, where it increases insulinstimulated glucose uptake, and in turn stimulates
insulin sensitivity. Hence, the increase in the level of
circulating chemerin is a compensatory metabolism in
patient with insulin resistance.
In our study, there is a positive correlation between
chemerin concentration levels and hs-CRP index in
end-stage renal disease patients. This was in agreement
with the study by Bozaoglu et al. [14], who suggested
that chemerin is a chemotactic agent that was recently
identified as the ligand of ChemR23, a serpentine
receptor expressed by activated macrophages and
monocyte-derived dendritic cells, as previously mentioned. This fact suggests a key role of the ChemR23/
chemerin axis in directing plasmacytoid dendritic
cell trafficking, which can play a significant role in
regulating the immune response by enhancing chemoattraction of the cells of the immune response toward
sites of pathological inflammation.
The diagnostic performance of serum chemerin in
detecting patients with renal impairment and under
hemodialysis and control healthy persons revealed that
the best cutoff level for chemerin in patient groups
was greater than 147.5 ng/ml, with a diagnostic
sensitivity, diagnostic specificity, positive predictive
value, negative predictive value, and efficiency of 100,
100, 100, and 100%, respectively, and an area under the
curve of 100.
The diagnostic performance of serum chemerin in
detecting patients with renal impairment and under
hemodialysis reveals that the best cutoff level
for chemerin was 249 ng/ml, with a diagnostic
sensitivity, diagnostic specificity, positive predictive
value, negative predictive value, and efficiency of
100, 90, 90.9, and 100%, respectively, and an AUC
of 99.2.
An association of chemerin serum levels with metabolic
syndrome-related parameters, including BMI [28],
fasting insulin (FI), TGs [29], HDL-cholesterol
[28], leptin [29], and C.reactive protein (CRP) [28],
has been shown. In agreement with these findings,
chemerin is positively correlated with BMI, FI, and
CRP, whereas GFR remains independently associated
with circulating chemerin. Interestingly, GFR also
independently predicts chemerin serum levels in the
CKD patients, which indicates that renal function is a
significant predictor of circulating chemerin not only in
subjects with (near) normal glomerular filtration but
also in patients with end-stage renal disease.
Conclusion
We found a significantly higher chemerin level in
patients with impaired kidney function compared with
normal control group and much increase in patients
under hemodialysis compared with the other two groups.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
1 Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, et al.
FGF23 inhibits extra-renal synthesis of 1,25-dihydroxyvitamin D in human
monocytes. J Bone Miner Res 2012; 28:46–55.
2 Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al.
Definition and classification of chronic kidney disease: a position statement
from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int
2005; 67:2089–2100.
3 Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National
Kidney Foundation practice guidelines for chronic kidney disease:
evaluation, classification, and stratification. Ann Intern Med 2003; 139:
137–147.
4 Johnson D. CKD screening and management: overview [chapter 4]. In
Daugirdas J. Handbook of chronic kidney disease management. Lippincott
Williams & Wilkins; 2011. 32–43.
5 Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and
regression of renal lesions of chronic nephropathies and diabetes. J Clin
Investig 2006; 116:288–296.
6 Sell H, Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo
and in vitro evidence for a possible causal correlation? Proc Nutr Soc 2009;
24:1–7.
7 Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le poul E, Migeotte L, et
al. Specific recruitment of antigen-presenting cells by chemerin, a novel
processed ligand from human inflammatory fluids. J Exp Med 2003;
198:977–985.
8 Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J. Chemerin activation by
serine proteases of the coagulation, fibrinolytic, and inflammatory
cascades. J Biol Chem J 2005; 280:34661–34666.
9 Goralski KB, et al. Chemerin: a novel adipokine that regulates adipogenesis
and adipocyte metabolism. J Biol Chem 2007; 282:28175–28188.
10 Cash JL, Hart R, Russ A, Dixon JPC. Synthetic chemerin-derived peptides
suppress inflammation through ChemR23. J Exp Med 2008; 205:767–775.
11 Du XY, Zabel BA, Mylest T, Allen SJ, Handel T, Lee P, et al. Regulation of
chemerin bioactivity by plasma corboxypeptidas n, corbox b (activated
thrombin activable fibrinolysis inhibitor), and platelets. J Bio Chem 2009;
284:751–758.
Serum chemerin level in CKD Abd Rabo et al.
12 Yoshimura T, Oppenhein JJ. Chemerin reveals it chimeric nature. J Exp
Med 2008; 205:2187–2190.
13 Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS,
Kitazawa R, et al. Chemerin enhances insulin signaling and potentiates
insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008;
582:573–578.
107
21 Dorte P, Anette B, Matthias B, Micheal S, Jurgen K. Serum levels of the
adipokine chemerin in relation to renal function. Diabetes Care 2012;
33:171–173.
22 Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, KalantarZadeh K. Association between serum lipids and survival in hemodialysis
patients and impact of race. J Am Soc Nephrol 2007; 18:293–303.
14 Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al.
Chemerin is a novel adipokine associated with obesity and metabolic
syndrome. Endocrinology 2007; 148:4687–4694.
23 Adlar AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development
and progression of nephropathy in type 2 diabetes: the United Kingdom
Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225–232.
15 Pfau D, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M,
Fasshauer M. Serum levels of the adipokine chemerin in relation to
renal function. Diabetes Care 2009; 33:171–173.
24 Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L. A
proposed nomenclature and diagnostic criteria for protein–energy wasting
in acute and chronic kidney disease. Kidney Int 2008; 73:391–398.
16 Friedwald WT, Levy RI, Frederickson DS. Estimation of the concentration
of low density lipoprotein cholesterol in plasma without use of the
preparative ultracentrifuge. Clin Chem 1972; 18:499.
25 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic
inflammation in fat plays a crucial role in the development of
obesity–related insulin resistance. J Clin Invest 2003; 112:1821–1830.
17 Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Peteiro J, GarciaNaveiro R, Garcia-Buela J. Plasma ghrelin in patients undergoing
haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004;
19:2095–2100.
26 Lehrke M, Becker A, Greif M, Stark R, Laubender RP, Von Ziegler F,
Lebherz C, et al. Chemerin is associated with markers of inflammation and
components of the metabolic syndrome but does not predict coronary
atherosclerosis. Eur J Endocrinol 2009; 161:339–344.
18 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling.
Clinical Neph 2004; 27:1487–1495.
27 Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al.
Systemic chemerin is related to inflammation rather than obesity in type 2
diabetes. Clin Endocrinol 2010; 395:106–110.
19 Grad E, Pachino RM, Fitzgerald GA, Danenberg HD. Role of thromboxane
receptor in C-reactive protein-induced thrombosis. Arterioscler Thromb
Vasc Biol 2012; 32:2468–2474.
20 Chu SH, Lee MK, Ahnk Y, Im JA, Park MS, Lee DC, et al. Chemerin and
adiponectin contribute reciprocally to metabolic syndrome. PloS One 2012;
7:e34710.
28 Ikizler TA. Resolved: being fat is good for dialysis patients: the Godzilla
effect: pro. J Am Soc Nephrol 2008; 19:1059–1062.
29 Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R,
Heimburger O, et al. Truncal fat mass as a contributor to inflammation in
end-stage renal disease. Am J Clin Nutr 2004; 80:1222–1229.